证券日报网讯 2月27日，迪哲医药发布2025年度业绩快报公告称，公司2025年实现营业总收入80113.56 万元，同比增长122.60%。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月27日，迪哲医药发布公告称，华泰联合证券更换公司持续督导保荐代表人，蓝图先生 接替许超先生，与丁明明先生共同负责公司IPO及2023年度定增的持续督导，督导期至2027年12月31 日。 ...

迪哲医药表示，作为全球源创新药的研发公司，持续的研发投入是公司实现高质量发展的关键支撑，因 此对于创新药的持续研发投入是影响公司经营财务状况的主要因素之一。本报告期是公司两款产品纳入 国家医保的第一个会计年度，销售呈现快速放量，实现产品合计销售收入8.01亿元；随着产品陆续上 市，产品销售收入和销售推广费用将成为影响公司经营财务状况的主要因素。 北京商报讯（记者 丁宁）2月27日晚间，迪哲医药（688192）发布2025年度业绩快报显示，报告期内， 公司实现营业收入约为8.01亿元，同比增长122.6%；归属净利润为-7.63亿元，同比实现减亏。 ...

业绩快报显示，2025年，公司已获批的两款产品舒沃哲®（通用名：舒沃替尼片）和高瑞哲®（通用 名：戈利昔替尼胶囊）均已首次纳入国家医保药品目录，有助于大幅提升患者的可及性，同时公司加大 产品推广，积极扩大产品市场份额，对公司经营产生了积极影响。 北京商报讯（记者 王寅浩 宋雨盈）2月27日，迪哲医药发布2025年业绩快报，2025年度公司实现营业总 收入8.01亿元，同比增长122.6%；归属于母公司所有者的净亏损为7.63亿元，上年同期为8.46亿元。 ...

作为全球源创新药的研发公司，持续的研发投入是公司实现高质量发展的关键支撑，因此对于创新药的 持续研发投入是影响公司经营财务状况的主要因素之一。本报告期是公司两款产品纳入国家医保的第一 个会计年度，销售呈现快速放量，实现产品合计销售收入8.01亿元；随着产品陆续上市，产品销售收入 和销售推广费用将成为影响公司经营财务状况的主要因素。 格隆汇2月27日丨迪哲医药(688192.SH)公布2025年度业绩快报，2025年度，公司实现营业总收入8.01亿 元；实现营业利润-7.66亿元；实现归属于母公司所有者的净利润-7.63亿元；实现归属于母公司所有者 的扣除非经常性损益的净利润-8.42亿元。 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2026-010 迪哲（江苏）医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）于近日收到持续督导 保荐机构华泰联合证券有限责任公司（以下简称"华泰联合"）出具的《关于更 换迪哲（江苏）医药股份有限公司首次公开发行股票及 2023 年度向特定对象发 行 A 股股票持续督导保荐代表人的函》。 公司首次公开发行股票并于 2021 年 12 月 10 日在上海证券交易所科创板上 市，聘请了中信证券股份有限公司（以下简称"中信证券"）担任首次公开发行 股票并在科创板上市的保荐机构，中信证券指派丁元女士、彭浏用先生担任保荐 代表人，持续督导期至 2024 年 12 月 31 日止。 公司于 2023 年 3 月 24 日召开第一届董事会第十六次会议、于 2023 年 4 月 14 日召开 2022 年年度股东大会，审议通过了《2023 年度向特定对象发行 A 股 股票预案》等相关议案。 ...

迪哲（江苏）医药股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以公司2025年年度报告为准，提请投资者注意投资风险。 | | | | 单位：万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅 度（％） | | 营业总收入 | 80,113.56 | 35,990.06 | 122.60 | | 营业利润 | -76,636.27 | -94,130.10 | 不适用 | | 利润总额 | -76,638.84 | -93,965.13 | 不适用 | | 归属于母公司所有者的净利润 | -76,331.12 | -84,595.63 | 不适用 | | 归属于母公司所有者的扣除非经常性损 益的净利润 | -84,155.30 | -89,889.00 | 不适用 | | 基本每股收益（元） | -1.71 | -2.04 | 不适用 | ...

迪哲医药发布业绩快报，2025年营业收入8.01亿元，同比增长122.60%。归属于母公司所有者的净利 润-7.63亿元，上年同期为-8.46亿元。报告期内，公司实现营业收入8.01亿元，较上年度增长122.60%。 2025年，公司已获批的两款产品舒沃哲®（通用名：舒沃替尼片）和高瑞哲®（通用名：戈利昔替尼胶 囊）均已首次纳入国家医保药品目录，有助于大幅提升患者的可及性，同时公司加大产品推广，积极扩 大产品市场份额，对公司经营产生了积极影响。 ...

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].